Merck & Co. (MRK) announced Friday morning that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of ELONVA, as a treatment in controlled ovarian stimulation in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology program. Merck & Co. rose during the first half hour of trade Friday and took out the highs of the session around mid-afternoon. Shares finished higher by $1.13 at $36.46. The stock has been on an upward trend for over 2 weeks and set its fifth consecutive new high for the year.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.